Life sciences company Entegrion will exhibit at the annual Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference in Florida this week. The ATACCC is the DOD's premier scientific meeting, addressing critical advances in trauma medicine and the unique medical needs of the warfighter. Nearly all of DOD's combat casualty care scientists will present their latest research results at the conference.
At last year’s conference, Dr. Fischer, Entegrion’s chief scientific officer and inventor of Staslion ™ delivered several presentations to military combat casualty care experts on products that Entegrion had in development to aid in preserving the life of military personnel. At this year’s conference, Entegrion’s booth will showcase the Stasilon™ textile technology – a FDA cleared medical textile that stops bleeding – and two other products in development, Stasix ® and Resusix ™. Entegrion invented the Stasilon™ technology in consultation with the Office of Naval Research to address the military’s crucial need for effective, but low-cost, hemostatic wound dressings.
The first bandage application of the technology, Stasilon™ - FR for first responders, is currently in the hands of men and women in our armed forces and other government agencies through distribution at LC Industries-operated military base supply centers across the country.
About Entegrion
Entegrion is a life sciences company that selectively integrates synergistic technologies with those in its patent portfolio for development of novel devices and drugs for hemorrhage control, resuscitation and associated tissue repair. The company is based in North Carolina’s Research Triangle Park, and is the inventor of Stasilon™ – the hemostatic medical textile technology cleared by the FDA for use by prescription and also by consumers – from which multiple hemorrhage control products are being made.
Building upon technologies licensed from the University of North Carolina, Entegrion’s portfolio includes platelet-derived platform technologies that are being developed as topical gels and sprays for tissue repair, infusible hemostatic agents for the control of internal hemorrhage, and novel vehicles for delivery of drugs to targeted tumors and other sites of internal bleeding. Entegrion has also developed proprietary techniques for drying plasma and other blood components to provide for long shelf life with rapid rehydration for emergent and clinical use. For more information, visit www.entegrion.com.
